The global market for glucagon like peptide-1 (glp-1) agonists is expected to grow from $ 7,621.2 million in 2021 to $ 14,228.9 million in 2026. The market is expected to grow at a CAGR of 13.3% over the forecast period (2021-2026). Some of the market's key participants are Amylin, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GSK, Novo Nordisk, Sanofi. This report intends to identify significant growth areas and to explore relevant market strategies. This in-depth analysis delves into the global market for glucagon like peptide-1 (glp-1) agonists. The primary goal of this research is to examine the potential growth areas, significant trends, and the market's impact on the industry. The report also reviews the adoption of glucagon like peptide-1 (glp-1) agonists in both established and emerging markets.
This study offers a thorough examination of global markets, as well as detailed profiles of key market participants, a revenue product portfolio, and current activities. This research looks into trends and dynamics like drivers, restraints, challenges, and opportunities. This study discusses the strategies used by developing industry participants, as well as advice for new market entrants. This research study examines market sizes in the past, present, and future.
The market segmented in this report into type and application.
In this report, the following geographic regions were considered for market research:
Key data were derived from various sources, including government agencies in Canada, China, India, Japan, the European Union, and the United States. International organizations also contributed raw data for final estimates. Estimated market trends were derived from annual reports, investor presentations, SEC filings, product portfolios, and news announcements. Data was gathered from the market's major end-users. Statistical studies were used to confirm global and regional market sales data for current and anticipated values.
1. Introduction
2. Market Overview
2.1. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Introduction
2.2. Macro- Economic Factor
2.3. Market Determinants
2.3.1. Market Driver
2.3.2. Market Restraints
2.3.3. Market Opportunities
2.3.4. Market Challenges
2.4. Technology/Product Roadmap
2.5. PEST Analysis
2.6. Market Growth Opportunity Analysis
2.7. Impact of Covid-19 on Glucagon Like Peptide-1 (GLP-1) Agonists Market
3. Market Segmentation
3.1. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis (US$ Mn), By Type, 2019 - 2026
3.1.1 Exenatied
3.1.2 Liraglutide
3.1.3 Lixisenatide
3.1.4 Albiglutide
3.1.5 Dulaglutide
3.2. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis (US$ Mn), By Application, 2019 - 2026
3.2.1 Hospital
3.2.2 Pharmacy
3.2.3 Other
4. Regional Analysis
4.1. North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis (US$ Mn), 2019 - 2026
4.1.1. By Country
4.1.1.1. U.S.
4.1.1.2.Canada
4.1.2.By Type
4.1.3.By Application
4.2.Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis (US$ Mn), 2019 - 2026
4.2.1.By Country
4.2.1.1.Germany
4.2.1.2.U.K.
4.2.1.3.France
4.2.1.4.Italy
4.2.1.5.Spain
4.2.1.6.Rest of Europe
4.2.2.By Type
4.2.3.By Application
4.3.Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis (US$ Mn), 2019 - 2026
4.3.1.By Country
4.3.1.1.China
4.3.1.2.Japan
4.3.1.3.India
4.3.1.4.Rest of Asia Pacific
4.3.2.By Type
4.3.3.By Application
4.4.Rest of world Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis (US$ Mn), 2019 - 2026
4.4.1. By Region
4.4.1.1. Middle East & Africa
4.4.1.2. Latin America
4.4.2.By Type
4.4.3. By Application
5.Company Profiles
5.1 Amylin
5.2 AstraZeneca
5.3 Bristol-Myers Squibb
5.4 Eli Lilly
5.5 GSK
5.6 Novo Nordisk
5.7 Sanofi